drugset / Trial / NCT05514444
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of MK-4464 as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.
Timeline
- Start
- 2022-09-25
- Primary completion
- 2025-09-18
- Completion
- 2025-09-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-4464 | Unknown | — | Intravenous |
| Background | 89Zr-MK-4464 | Unknown | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |